Newer developments in the treatment of Gram-positive infections

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)

(2016) Lala Dunbar   Therapeutics and Clinical Risk Management

Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil

(2010) J.L. Kuti et al.   CLINICAL MICROBIOLOGY AND INFECTION

Iclaprim, a Novel Diaminopyrimidine for the Treatment of Resistant Gram-Positive Infections

(2009) Carrie A Sincak et al.   ANNALS OF PHARMACOTHERAPY

In Vivo Pharmacodynamic Profile of Tigecycline against Phenotypically Diverse Escherichia coli and Klebsiella pneumoniae Isolates

(2009) A. M. Nicasio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rationale for Revised Penicillin Susceptibility Breakpoints versusStreptococcus pneumoniae:Coping with Antimicrobial Susceptibility in an Era of Resistance

(2009) Melvin P. Weinstein et al.   CLINICAL INFECTIOUS DISEASES

Relationship between Initial Vancomycin Concentration‐Time Profile and Nephrotoxicity among Hospitalized Patients

(2009) Thomas P. Lodise et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008)

(2009) Helio S. Sader et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

(2008) M. Rybak et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

In Vivo Microdialysis Study of the Penetration of Daptomycin into Soft Tissues in Diabetic versus Healthy Volunteers

(2008) A. Kim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of Tigecycline against Phenotypically Diverse Staphylococcus aureus Isolates in a Murine Thigh Model

(2008) J. L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria

(2008) K. M. Krause et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamic Characterization of Ceftobiprole in Experimental Pneumonia Caused by Phenotypically Diverse Staphylococcus aureus Strains

(2008) S. Laohavaleeson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection Models

(2008) W. A. Craig et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dalbavancin: a Novel Once-Weekly Lipoglycopeptide Antibiotic

(2008) L. D. Saravolatz et al.   CLINICAL INFECTIOUS DISEASES

A Randomized, Double-Blind Trial Comparing Ceftobiprole Medocaril with Vancomycin plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-Structure Infections

(2008) G. J. Noel et al.   CLINICAL INFECTIOUS DISEASES

Complicated Skin and Skin‐Structure Infections and Catheter‐Related Bloodstream Infections: Noninferiority of Linezolid in a Phase 3 Study

(2008) Mark H. Wilcox et al.   CLINICAL INFECTIOUS DISEASES

Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens

(2008) Garyphallia Poulakou et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Pharmacoeconomics of linezolid

(2008) Santiago Grau et al.   EXPERT OPINION ON PHARMACOTHERAPY

Emergence and management of drug-resistant enterococcal infections

(2008) Cesar A Arias et al.   Expert Review of Anti-Infective Therapy

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens

(2008) Jared Crandon et al.   Future Microbiology

Interactions of antimicrobial compounds with cross-linking agents of alginate dressings

(2008) C. H. Goh et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Tigecycline pharmacokinetic/pharmacodynamic update

(2008) A. P. MacGowan   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study

(2008) I. Florescu et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence

(2008) D. E. Karageorgopoulos et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pharmacokinetic-Pharmacodynamic Modeling of Dalbavancin, a Novel Glycopeptide Antibiotic

(2008) James A. Dowell et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Oritavancin Exhibits Dual Mode of Action to Inhibit Cell-Wall Biosynthesis in Staphylococcus aureus

(2008) Sung Joon Kim et al.   JOURNAL OF MOLECULAR BIOLOGY